These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9598774)

  • 41. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
    Dong SX; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.
    Toh HS; Chuang YC; Huang CC; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Ko WC; Yu KW; Liu YC; Chen YS; Tang HJ; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S18-23. PubMed ID: 22749054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species.
    Chin NX; Neu HC
    Chemotherapy; 1987; 33(3):183-8. PubMed ID: 3109815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of isepamicin and beta-lactam antibiotics on the release of endotoxin from Pseudomonas aeruginosa].
    Yamaguchi S; Sato S; Toriya M; Tsuji A
    Jpn J Antibiot; 1999 Jan; 52(1):41-56. PubMed ID: 10202687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients].
    Maugein J; Perrier F; Cony Makhoul P; Fourche J; Darmaillac V
    Pathol Biol (Paris); 1995 Apr; 43(4):253-7. PubMed ID: 7567110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
    Fujiue Y; Kuwabara M; Muroki K; Shimizu S; Watanabe Y; Awaya Y; Kodomari Y
    Jpn J Antibiot; 1998 Jan; 51(1):26-36. PubMed ID: 9557274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Further studies of transferable antibiotic resistance in strains of Pseudomonas aeruginosa from four clinical settings in three countries.
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K; Torsová V; Bartoníková N; Schäfer V
    J Chemother; 1998 Jun; 10(3):215-20. PubMed ID: 9669646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
    Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
    Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
    Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.